Letter: rationalising aminosalicylates in inflammatory bowel disease—authors' reply-Reference-Cited by-同舟云学术

Letter: rationalising aminosalicylates in inflammatory bowel disease—authors' reply

Published:2020-10-21 Issue:10 Volume:52 Page:1621-1621
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Chapman Thomas P.¹²^ORCID,Frias Gomes Catarina³^ORCID,Louis Edouard⁴,Colombel Jean‐Frédéric⁵^ORCID,Satsangi Jack¹

Affiliation:

1. Translational Gastroenterology Unit Nuffield Department of Experimental Medicine University of Oxford Oxford UK

2. Department of Gastroenterology Western Sussex Hospitals NHS Foundation Trust Worthing UK

3. Surgical Department Gastroenterology Division Hospital Beatriz Ângelo Loures Portugal

4. Department of Gastroenterology CHU Liège University Hospital Liège Belgium

5. The Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai New York City NY USA

Abstract

LINKED CONTENTThis article is linked to Chapman et al and Nicolaides et al papers. To view these articles, visithttps://doi.org/10.1111/apt.15771andhttps://doi.org/10.1111/apt.16107

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16113

Reference6 articles.

1. Letter: rationalising aminosalicylates in inflammatory bowel disease;Nicolaides S;Aliment Pharmacol Ther,2020

2. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease

3. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy

4. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

5. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study